Quick Answer
CRISPR Therapeutics AG reported Cash and Equivalents of $347.56 million for fiscal year 2025.
CRISPR Therapeutics AG Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $347.56M | +16.5% |
| 2024 | $298.26M | -23.4% |
| 2023 | $389.48M | +83.8% |
| 2022 | $211.88M | -77.0% |
| 2021 | $923.03M | -21.0% |
| 2020 | $1.17B | +23.8% |
| 2019 | $943.77M | +106.7% |
| 2018 | $456.65M | +90.5% |
| 2017 | $239.76M | -24.0% |
| 2016 | $315.52M | +102.3% |
| 2015 | $155.96M | +16403.8% |
| 2014 | $945.0K | +161.8% |
| 2013 | $361.0K | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $286.50M | +27.0% | +48.0% |
| June 30, 2025 | $193.62M | -60.0% | -17.7% |
| March 31, 2025 | $235.18M | -66.8% | -21.1% |
| December 31, 2024 | $298.26M | -23.4% | +32.2% |
| September 30, 2024 | $225.67M | -57.2% | -53.4% |
| June 30, 2024 | $484.47M | +8.9% | -31.5% |
| March 31, 2024 | $707.43M | +105.4% | +81.6% |
| December 31, 2023 | $389.48M | +83.8% | -26.2% |
- CRISPR Therapeutics AG showed an increase of +16.5% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2013–2025 period, CRISPR Therapeutics AG’s cash and equivalents has grown by 96176.7% (from $361.0 thousand to $347.56 million).
- The most recent figure is from CRISPR Therapeutics AG’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: